

Roberto Sorio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2067993/publications.pdf>

Version: 2024-02-01

128
papers

5,667
citations

147801

31
h-index

79698

73
g-index

130
all docs

130
docs citations

130
times ranked

6086
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1302-1308.	1.6	1,240
2	Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 66-72.	6.3	901
3	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 396-405.	10.7	327
4	Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3628-3635.	1.6	182
5	A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9845-9850.	7.1	176
6	Hepatitis C virus and non-Hodgkin's lymphomas. <i>British Journal of Haematology</i> , 1996, 94, 544-550.	2.5	171
7	Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1309-1316.	1.6	154
8	Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. <i>International Journal of Cancer</i> , 1998, 79, 121-126.	5.1	138
9	Uterine cervical carcinoma: Role of matrix metalloproteinases (Review). <i>International Journal of Oncology</i> , 2009, 34, 897-903.	3.3	103
10	Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. <i>Clinical Cancer Research</i> , 2007, 13, 6410-6418.	7.0	101
11	Development and validation of a microRNA-based signature (MiROvar) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. <i>Lancet Oncology</i> , The, 2016, 17, 1137-1146.	10.7	97
12	Entry and evaluation of elderly patients in european organization for research and treatment of cancer (EORTC) new-drug development studies. <i>Cancer</i> , 1995, 76, 333-338.	4.1	96
13	Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. <i>European Journal of Cancer</i> , 1997, 33, 301-303.	2.8	75
14	Pharmacokinetics of vinorelbine in patients with liver metastases. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 32-40.	4.7	72
15	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	10.7	68
16	Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3347-3353.	1.6	66
17	CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. <i>EMBO Molecular Medicine</i> , 2017, 9, 1415-1433.	6.9	61
18	EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. <i>European Journal of Cancer</i> , 1996, 32, 2019-2022.	2.8	60

#	ARTICLE	IF	CITATIONS
19	Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. <i>Annals of Oncology</i> , 2016, 27, 487-493.	1.2	51
20	Revisiting the Clinical Value of 18F-FDG PET/CT in Detection of Recurrent Epithelial Ovarian Carcinomas. <i>Clinical Nuclear Medicine</i> , 2012, 37, e184-e188.	1.3	50
21	Population pharmacokinetics and pharmacodynamics of oral etoposide. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 511-519.	2.4	48
22	Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1418-1426.	1.6	46
23	Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 287-294.	2.3	44
24	Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. <i>BMC Cancer</i> , 2008, 8, 252.	2.6	44
25	Surgical and Medical Treatment of Clear Cell Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1063-1070.	2.5	43
26	Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2007, 46, 1051-1068.	3.5	42
27	Final results from GCG/ENGOT/AGO-EOVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. <i>International Journal of Cancer</i> , 2020, 146, 439-448.	5.1	40
28	Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 167-171.	2.3	37
29	Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5502-5502.	1.6	34
30	Long-Term, weekly One-Hour Infusion of Paclitaxel in Patients with Metastatic Breast Cancer: A Phase II Monoinstitutional Study. <i>Tumori</i> , 2004, 90, 285-288.	1.1	33
31	Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 233-241.	4.4	32
32	The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2. <i>European Journal of Cancer</i> , 1994, 30, 329-333.	2.8	31
33	Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. <i>Annals of Oncology</i> , 2002, 13, 777-780.	1.2	31
34	Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer. <i>Oncology</i> , 2006, 71, 320-326.	1.9	30
35	Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial. <i>Oncology</i> , 2009, 76, 49-54.	1.9	30
36	Determination of unbound etoposide concentration in ultrafiltered plasma by high-performance liquid chromatography with fluorimetric detection. <i>Biomedical Applications</i> , 1996, 686, 35-41.	1.7	29

#	ARTICLE	IF	CITATIONS
37	Carboplatin and paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2011, 105, 360-365.	6.4	28
38	Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. <i>Scientific Reports</i> , 2017, 7, 7104.	3.3	28
39	Epirubicin and ifosfamide in advanced soft tissue sarcomas. <i>Annals of Oncology</i> , 1993, 4, 669-672.	1.2	26
40	A Phase II Study of Oral Idarubicin (4-Demethoxydaunorubicin) in Previously Untreated Elderly Patients with Non-Hodgkin's Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1991, 14, 243-245.	1.3	25
41	Genetic profiling and ovarian cancer therapy (Review). <i>Molecular Medicine Reports</i> , 2011, 4, 771-7.	2.4	25
42	New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. <i>Cells</i> , 2019, 8, 584.	4.1	25
43	Combination Chemotherapy Specifically Devised for Elderly Patients with Unfavorable Non-Hodgkin's Lymphoma. <i>Cancer Investigation</i> , 1990, 8, 577-582.	1.3	24
44	Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer. <i>Investigational New Drugs</i> , 2003, 21, 347-352.	2.6	22
45	Multimodality approach in extra cervical locally advanced cervical cancer: Chemoradiation, surgery and intra-operative radiation therapy. A phase II trial. <i>European Journal of Surgical Oncology</i> , 2011, 37, 442-447.	1.0	22
46	Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion. <i>Cancer Chemotherapy and Pharmacology</i> , 1987, 20, 239-242.	2.3	21
47	Hodgkin's disease in patients with HIV infection and in the general population: Comparison of clinicopathological features and survival. <i>Annals of Oncology</i> , 1994, 5, S37-S40.	1.2	21
48	Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. <i>BMC Cancer</i> , 2006, 6, 202.	2.6	21
49	Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. <i>Gynecologic Oncology</i> , 2017, 144, 65-71.	1.4	21
50	Sensitive high-performance liquid chromatographic method with fluorescence detection for measurement of vinorelbine plasma concentrations. <i>Biomedical Applications</i> , 1996, 675, 183-187.	1.7	20
51	A study from the EORTC new drug development group: Open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer. <i>European Journal of Cancer</i> , 2006, 42, 200-204.	2.8	20
52	Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. <i>Annals of Oncology</i> , 2006, 17, 807-812.	1.2	20
53	A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). <i>Gynecologic Oncology</i> , 2013, 130, 31-37.	1.4	20
54	TIMP-1 Is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells. <i>Cells</i> , 2020, 9, 6.	4.1	20

#	ARTICLE	IF	CITATIONS
55	Phase II Study of Sequential Administration of Docetaxel Followed by Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 3367-3375.	1.6	18
56	Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0140351.	2.5	17
57	A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer. <i>Investigational New Drugs</i> , 2005, 23, 85-89.	2.6	15
58	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. <i>Oncotarget</i> , 2016, 7, 72654-72661.	1.8	15
59	A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of paclitaxel and 6 \pm -hydroxy-paclitaxel in human plasma: Development, validation and application in a clinical pharmacokinetic study. <i>PLoS ONE</i> , 2018, 13, e0193500.	2.5	14
60	Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide. <i>British Journal of Cancer</i> , 1997, 75, 715-721.	6.4	13
61	Local chemotherapy for neoplastic pericardial effusion. <i>American Journal of Cardiology</i> , 2000, 86, 1292.	1.6	13
62	The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5505-5505.	1.6	13
63	Acute morphine intoxication during high-dose recombinant interleukin-2 treatment for metastatic renal cell cancer. <i>European Journal of Cancer</i> , 1994, 30, 1905-1907.	2.8	12
64	Cisplatin may be a Valid Alternative Approach in Ovarian Carcinoma with Carboplatin Hypersensitivity. Report of Three Cases. <i>Tumori</i> , 2003, 89, 311-313.	1.1	12
65	A Phase II Study of Liposomal Doxorubicin in Recurrent Epithelial Ovarian Carcinoma. <i>Tumori</i> , 2004, 90, 556-561.	1.1	12
66	Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study. <i>Journal of Ovarian Research</i> , 2014, 7, 72.	3.0	12
67	<sc><i>CDKN1B</i></sc> mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer. <i>Journal of Pathology</i> , 2021, 253, 234-245.	4.5	12
68	Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives. <i>Cancers</i> , 2021, 13, 3035.	3.7	12
69	Resistance to methotrexate in SKOV-3 cell lines after chronic exposure to carbamazepine is associated with a decreased expression of folate receptor. , 2000, 85, 683-690.		11
70	Ifosfamide in Advanced/Disseminated Breast Cancer. <i>Oncology</i> , 2003, 65, 55-58.	1.9	11
71	A centralized Pharmacy Unit for cytotoxic drugs in accordance with Italian legislation. <i>Journal of Evaluation in Clinical Practice</i> , 2007, 13, 265-271.	1.8	11
72	Phase II studies of 4 β -iodo-4 α -deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers. <i>Annals of Oncology</i> , 1991, 2, 727-731.	1.2	10

#	ARTICLE	IF	CITATIONS
73	Should elderly cancer patients be entered in dose-escalation studies?. <i>Annals of Oncology</i> , 1994, 5, 964-965.	1.2	10
74	Reversal activity of cyclosporin A and its metabolites M1, M17 and M21 in multidrug-resistant cells. , 1997, 71, 900-906.		10
75	Paraneoplastic cerebellar degeneration associated with ovarian cancer. <i>Oncology Letters</i> , 2013, 5, 681-683.	1.8	10
76	Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS). <i>International Journal of Molecular Sciences</i> , 2018, 19, 1510.	4.1	10
77	Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC). <i>Cells</i> , 2019, 8, 1186.	4.1	10
78	Effect of cyclosporin A on protein binding of teniposide in cancer patients. <i>Anti-Cancer Drugs</i> , 1999, 10, 511-518.	1.4	9
79	Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. <i>Gynecologic Oncology</i> , 2019, 154, 83-88.	1.4	9
80	INCREASED PREVALENCE OF HTLV-III ANTIBODY AMONG DRUG ADDICTS FROM ITALIAN PROVINCE WITH US MILITARY BASE. <i>Lancet, The</i> , 1986, 327, 804.	13.7	8
81	Interactions of Antineoplastic Chemotherapy with Zidovudine Pharmacokinetics in Patients with HIV-Related Neoplasms. <i>Chemotherapy</i> , 1999, 45, 418-428.	1.6	8
82	Treatment of older breast cancer patients with high recurrence risk. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 241-246.	4.4	8
83	Vinorelbine-induced acute reversible peripheral neuropathy in a patient with ovarian carcinoma pretreated with carboplatin and paclitaxel. <i>Acta OncolÁgica</i> , 2004, 43, 209-211.	1.8	8
84	A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1021-1027.	2.3	8
85	A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1347-1353.	2.3	8
86	Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2018, 29, 1189-1194.	1.2	8
87	Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Final analysis of the MITO-2 randomized multicenter trial.. <i>Journal of Clinical Oncology</i> , 2010, 28, LBA5033-LBA5033.	1.6	7
88	HTLV-III INFECTION AMONG 315 INTRAVENOUS DRUG ABUSERS: SEROEPIDEMIOLOGICAL, CLINICAL, AND PATHOLOGICAL FINDINGS. <i>AIDS Research</i> , 1986, 2, 325-334.	0.5	6
89	Flavone acetic acid distribution in human malignant tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 67-70.	2.3	6
90	Evaluation of Two Consecutive Regimens in Advanced Gastric Cancer. <i>Cancer Investigation</i> , 1991, 9, 257-262.	1.3	6

#	ARTICLE	IF	CITATIONS
91	Natural killer (NK) and lymphokine activated killer (LAK) cell activity in patients (PTS) treated with favone acetic acid (FAA). <i>Annals of Oncology</i> , 1991, 2, 145-150.	1.2	6
92	Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Continuous Intravenous Infusion of Recombinant Interleukin-2: The Experience of a Single Institution. <i>Tumori</i> , 2003, 89, 400-404.	1.1	6
93	Gemcitabine and anthracyclines in platinum-resistant ovarian cancer. <i>Annals of Oncology</i> , 2006, 17, v195-v198.	1.2	6
94	Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 1999, 10, 815-820.	1.4	5
95	Carboplatin and Topotecan Combination and Myelosuppression. <i>Journal of Clinical Oncology</i> , 2002, 20, 3558-3558.	1.6	5
96	Oral Etoposide in Elderly Patients with Advanced Non Small Cell Lung Cancer: A Clinical and Pharmacological Study. <i>Journal of Chemotherapy</i> , 2006, 18, 188-191.	1.5	5
97	Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 986-992.	2.5	5
98	Multicenter Phase 2 Study of Combined Gemcitabine and Epirubicin as Second-Line Treatment for Patients With Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 953-957.	2.5	5
99	A TGF- β 2 associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 233-242.	1.4	5
100	Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): Activity and safety results of the MITO-2 randomized multicenter trial. <i>Journal of Clinical Oncology</i> , 2009, 27, LBA5508-LBA5508.	1.6	5
101	HTLV-III Antibodies in Drug-Addicted Prostitutes Used by US Soldiers in Italy. <i>JAMA - Journal of the American Medical Association</i> , 1986, 256, 711.	7.4	4
102	Liver Function Assessment by MEGX.. <i>Annals of the New York Academy of Sciences</i> , 1996, 784, 486-490.	3.8	4
103	Lapatinib-Based Therapy in Heavily Pretreated HER2-Positive Metastatic Breast Cancer: A Single Institution Experience. <i>Tumori</i> , 2012, 98, 33-38.	1.1	4
104	Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience. <i>Tumori</i> , 2012, 98, 33-8.	1.1	4
105	Phase II Study of Teniposide (VM26) in Cutaneous T-Cell Lymphomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1990, 13, 14-16.	1.3	3
106	Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 505-505.	2.4	3
107	Incidence of Palmar-Plantar Erythrodysesthesia in Pretreated and Unpretreated Patients Receiving Pegylated Liposomal Doxorubicin. <i>Tumori</i> , 2009, 95, 687-690.	1.1	3
108	Combination chemotherapy with fluorouracil, adriamycin, cis-Platinum and VM-26 in advanced transitional cell carcinoma of the urinary tract. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 1457-1460.	0.7	2

#	ARTICLE	IF	CITATIONS
109	Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorrhagic cystitis from ifosfamide (IFO). <i>Annals of Oncology</i> , 1992, 3, S115-S118.	1.2	2
110	Pharmacokinetic Comparison of 120-Hour Infusion Versus Hyperfractionated Oral Administration of Idarubicin. <i>Journal of Chemotherapy</i> , 2004, 16, 193-200.	1.5	2
111	Phase II prospective study on trabectedin (T) in BRCA-mutated and BRCAness phenotype advanced ovarian cancer (AOC) patients (pts): The MITO 15 trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 5530-5530.	1.6	2
112	Human immunodeficiency virus (HIV) infection among prisoners in Northeastern Italy. <i>Infection</i> , 1988, 16, 251-251.	4.7	1
113	Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project. <i>Supportive Care in Cancer</i> , 2017, 25, 1743-1748.	2.2	1
114	Phase II study on pemetrexed in advanced and/or recurrent cervical cancer patients: a MITO study. <i>Journal of Clinical Oncology</i> , 2008, 26, 5515-5515.	1.6	1
115	Gemcitabine (G) and epirubicin (E) combination, in platinum-resistant or refractory advanced ovarian cancer (PROC) patients: Results of a multicentric phase II trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 5566-5566.	1.6	1
116	Effect of cyclosporine on teniposide pharmacokinetics and pharmacodynamics in patients with renal cell cancer. <i>Anti-Cancer Drugs</i> , 1995, 6, 479-482.	1.4	0
117	Dose finding and pharmacokinetic (PK) study of daily oral Idarubicin (IDA) in metastatic breast cancer (MBC). <i>European Journal of Cancer</i> , 1997, 33, S251.	2.8	0
118	Anthracycline dose and liver dysfunction. <i>British Journal of Cancer</i> , 1999, 79, 1943-1943.	6.4	0
119	Pharmacology study of chronic oral idarubicin for breast cancer. <i>European Journal of Cancer</i> , 1999, 35, S291-S292.	2.8	0
120	Long term follow up of 50 patients with metastatic renal cell carcinoma treated with high dose i.v. interleukin. 2. <i>European Journal of Cancer</i> , 1999, 35, S358.	2.8	0
121	Occult Small Cell Lung Cancer Associated with Paraneoplastic Neurologic Syndrome: Case Report. <i>Tumori</i> , 2001, 87, 447-450.	1.1	0
122	Polymorphisms of MDR1 and MRP2/cMOAT in healthy North Eastern Italian subjects. <i>European Journal of Cancer</i> , 2002, 38, S156.	2.8	0
123	Carboplatin in Elderly Patients. <i>Tumori</i> , 2002, 88, S35-S36.	1.1	0
124	Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?. <i>Archives of Gynecology and Obstetrics</i> , 2012, 285, 499-503.	1.7	0
125	Idarubicin. <i>Reactions Weekly</i> , 2015, 1538, 128-128.	0.0	0
126	Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2008, 26, 2572-2572.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a randomized study. <i>Journal of Clinical Oncology</i> , 2008, 26, 594-594.	1.6	0
128	Abstract 332: B-Raf mutations are associated with a worse outcome in ovarian cancer. , 2011, , .		0